|
ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation.〔(【引用サイトリンク】title=ALK Inhibitors: Possible New Treatment for Lung Cancer )〕 ==EML4-ALK== About 4-7% of non-small cell lung carcinomas (NSCLC) have EML4-ALK translocations.〔 There are currently two ALK inhibitors, crizotinib (Xalkori) and ceritinib (Zykadia), approved by the FDA for treatment of NSCLC.〔(【引用サイトリンク】title=Non-Small-Cell Lung Cancer Standards of Care Challenged by a Cornucopia of New Drugs )〕〔(【引用サイトリンク】title=Crizotinib in ALK-NSCLC; Response Rate "Unprecedented" )〕 Additional ALK inhibitors currently (or soon to be) undergoing clinical trials include: * Alectinib (Chugai, NDA has been filed in Japan) (breakthrough status in U.S.) * Brigatinib (AP26113 by Ariad) (breakthrough status in U.S.) * Entrectinib (Nerviano's NMS-E628, licensed by Ignyta and renamed RXDX-101, in the U.S. orphan drug designation and rare pediatric disease designation for the treatment of neuroblastoma and orphan drug designation for treatment of TrkA-, TrkB-, TrkC-, ROS1- and ALK-positive NSCLC) * PF-06463922 (Pfizer) * TSR-011 (Tesaro) * CEP-37440 (Teva) * X-396 (Xcovery) Updates for several of these will be available at the start of June at ASCO 2014. Discontinued * ASP-3026 (Astellas) 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「ALK inhibitor」の詳細全文を読む スポンサード リンク
|